Wednesday, February 10, 2010, 5:53pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Immunomedics Inc. (IMMU)

At 5:00AM SGT: 3.10 USD   0.00 (0.00%)  
 MORE ON IMMU 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Immunomedics, Inc. (NGM:IMMU) Delayed quote dataEdit
Last Trade:3.10 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:3.10
Open:N/A
Bid:2.68 x 4500
Ask:3.40 x 200
1y Target Est:6.50
Day's Range:N/A - N/A
52wk Range:0.84 - 7.16
Volume:0
Avg Vol (3m):1,572,160
Market Cap:233.08M
P/E (ttm):6.50
EPS (ttm):0.48
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add IMMU to Portfolio   Download Data

 HEADLINES 
•IMMUNOMEDICS INC Financials
EDGAR Online Financials (Sat, Feb 6)
•Biotech Stock Mailbag: Soligenix
at TheStreet.com (Fri, Feb 5)
•New Star Analyst Rankings for Immunomedics, Inc.
StarMine (Wed, Feb 3)
•IMMUNOMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Tue, Feb 2)
•Immunomedics Announces Second Quarter Fiscal 2010 Results and Clinical Program Developments
GlobeNewswire (Tue, Feb 2)
•[$$] Live Nation Adds 15%; Umpqua, Spartan Fall
at The Wall Street Journal Online (Tue, Jan 26)
•New Targeted Therapy for Pancreatic Cancer Presented at Cancer Conference
GlobeNewswire (Mon, Jan 25)
•Immunomedics cites potential blood test for cancer
AP (Fri, Jan 22)
•New Blood Test for Detecting Early Stage Pancreatic Cancer Presented at Cancer Conference
GlobeNewswire (Thu, Jan 21)
•IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue, Jan 19)
More Headlines for IMMU...
 ANALYST 
EPS Est (next year) (Jun-10) :0.26
EPS Est (in 2 years) (Jun-11) :-0.32
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Immunomedics, Inc. engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, and autoimmune and other serious diseases.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices